在非小细胞肺癌中,患者对EGFR突变向治疗的偏好,重点是Exon 20插入
Jaein Seo1, Eileen Curran2, Jennifer A Whitty3
1PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA, USA.
Lung cancer (Amsterdam, Netherlands)
|October 29, 2025
概括
患有非小细胞肺癌 (NSCLC) 和EGFR突变的患者优先考虑治疗疗效,但也重视减少副作用和方便的治疗方案. 这些偏好应该指导未来的药物开发和临床决策.
科学领域:
- 在瘤学瘤学.
- 医学经济学 医学经济学
- 患者报告的结果
背景情况:
- 具有表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 提出了独特的治疗挑战.
- 包括exon 20插入 (ex20ins) 在内的EGFR突变需要了解患者的偏好,以获得最佳的治疗策略.
研究的目的:
- 调查EGFR突变的NSCLC患者的治疗偏好,特别关注益处,风险和管理之间的权衡.
- 量化疾病控制,减少不良事件和治疗方案在患者决策中的相对重要性.
主要方法:
- 招募了美国成年患有NSCLC和EGFR突变的患者队列.
- 使用一个多维值练习,包括适应性权衡问题,来评估患者的偏好和估计相对属性权重 (RAW).
主要成果:
- 将疾病控制率 (DCR) 从60%提高到90%是最重要的驱动因素 (RAW=33.1%).
- 降低严重腹风险 (RAW=18.1%) 和改善治疗方案 (RAW=15.2%) 也被高度评价.
- 患者愿意放弃DCR以减少严重的不良事件,并喜欢更简单的治疗方案.
结论:
- 患有EGFR突变的NSCLC患者表现出对疗效的强烈偏好,但也显著重视减少不良事件和治疗方案的便利性.
- 这些以患者为中心的偏好对于在这个人群中为未来药物开发和临床治疗决策提供信息至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K